Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 18/20 | 0.69 |
| ▸ | MAOA | P21397 | 13/20 | 0.69 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2939021 | 0.88 | MAOB (0.67) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL21383038 | 0.80 | MAOB (0.67) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL2330963 | 0.77 | PARP1 (0.44) | MAOBMAOACYP1A2CYP2C9 | |
| SCHEMBL4429069 | 0.76 | MAOB (0.57) | MAOBMAOAGRM5MEN1NPC1 | |
| SCHEMBL4429073 | 0.76 | MAOB (0.57) | MAOBMAOAGRM5MEN1NPC1 | |
| SCHEMBL4419819 | 0.76 | MAOB (0.85) | MAOBMAOAGRM5MEN1NPC1 | |
| SCHEMBL6439886 | 0.74 | MAOB (0.61) | MAOBMAOAGRM5MEN1NPC1 | |
| SCHEMBL2334456 | 0.73 | METAP1 (0.57) | MAOBMAOANPC1CYP1A2CYP2C9 | |
| SCHEMBL3759785 | 0.72 | MAOB (0.74) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL4418614 | 0.72 | MAOB (0.65) | MAOBMAOAGRM5MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501804-B1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| EP-1501804-A1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6818774-B2 | 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003091219-A1 | ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | MAOB, MAOA, BACE2 | MAOB 1/4885MAOA 2/4885GRM5 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.